-
-
Finance -
Pharma & Human Health -
Finance -
Editor's Choice
Editor’s Choice
Editor's Choice
EXPERT’Biome CDMO by Lallemand at Microbiome Times Forum
With Expert’Biome™, Lallemand Health Solutions aims to support partners in their development of next-generation strains by offering comprehensive services in the health industry. These services include strains research and development, bioprocesses scaling, drug manufacturing, and […]
Editor's Choice
DynaMAP – Precision Metagenomics beyond Sequencing
At the Microbiome Times Partnering Forum, Arno Bouwens, R&D Director at Perseus Biomics, took to the stage to present their technology, DynaMAP (Dynamic Microbiome Abundance Profiling), for high-resolution microbiome analysis. His talk, titled “DynaMAP – […]
Editor's Choice
The Selection of a Pre-Clinical Model is Driven by the Specific Research Question
At the Microbiome Times Partnering Forum, Massimo Marzorati, CEO of ProDigest, presents “The Selection of a Pre-Clinical Model is Driven by the Specific Research Question”. A talk highlighting the company’s expertise in simulating the gastrointestinal […]
In Case you Missed it:
Pharma & Human Health
Diagnostic and therapeutic use of the microbiota will become reality within the next 5-10 years
An article published in Cell summarizes results of research and possible future clinical applications of the microbiome and provides instructions for doctors. More communication is needed between basic and clinical research to accelerate the arrival […]
Pharma & Human Health
InnoGI Technologies Unveils its Advanced Gut Microbiome Model (TIM-2) By Incorporating Mucus
Introduction InnoGI Technologies a leading Contract Research Organization (CRO) specializing in gastrointestinal (GI) modeling, today announced promising results from a validation study of its enhanced in vitro colon model, TIM-2muc. By incorporating a physiologically relevant […]
Finance
32 Biosciences receives $6 million in funding to advance gut microbiome platform technologies
32 Biosciences announced it has received $6 million in funding to support the continued development of its lead assets. The funding comes as the company prepares for a future Series A fundraise and advances toward key […]
Finance
MaaT Pharma Submits Marketing Authorization Application to the European Medicines Agency (EMA) for Xervyteg®
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, announced the […]
Editor's Choice
DynaMAP – Precision Metagenomics beyond Sequencing
At the Microbiome Times Partnering Forum, Arno Bouwens, R&D Director at Perseus Biomics, took to the stage to present their technology, DynaMAP (Dynamic Microbiome Abundance Profiling), for high-resolution microbiome analysis. His talk, titled “DynaMAP – […]
Editor's Choice
The Selection of a Pre-Clinical Model is Driven by the Specific Research Question
At the Microbiome Times Partnering Forum, Massimo Marzorati, CEO of ProDigest, presents “The Selection of a Pre-Clinical Model is Driven by the Specific Research Question”. A talk highlighting the company’s expertise in simulating the gastrointestinal […]
Pharma & Human Health
A symbiotic gut fungus wards off liver disease in mice
Researchers have found a new ally in the fight against a serious liver disease: a symbiotic gut-dwelling fungus that produces a molecule shown to be capable of reversing disease progression in mice. The findings may […]
Pharma & Human Health
Study of facial bacteria could lead to probiotics that promote healthy skin
The composition of bacterial populations living on our faces plays a significant role in the development of acne and other skin conditions such as eczema. Two species of bacteria predominate in most people, but how […]
